Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06151717 · ClinicalTrials.gov registry record
A Comparative Clinical Study to Determine the Optimal Initial Therapy for Multiple Myeloma
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 50
- Enrollment target
NCT06151717: Completed study, sponsored by Mayo Clinic.
NCT06151717 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06151717 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
Study Summary
This study evaluates the outcomes of patients undergoing initial therapy for multiple myeloma.
Primary Outcome
Overall survival, defined as the time from initiation of therapy to the time of death due to any cause, will be assessed by review of medical record, contacting the participant, or contacting the participant's local physician every 3 months for up to 10 years after participant starts the study.
Interventions
- OTHER Non-Interventional Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-09-21 |
| Est. Completion | 2025-06-05 |
What the finished NCT06151717 record still lists
NCT06151717 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Non-Interventional Study is the first listed.
NCT06151717 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06151717 about?
NCT06151717 is a clinical study titled "A Comparative Clinical Study to Determine the Optimal Initial Therapy for Multiple Myeloma". This study evaluates the outcomes of patients undergoing initial therapy for multiple myeloma.
What is the current status of trial NCT06151717?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2023-09-21. Estimated completion is 2025-06-05.
What interventions are being tested in trial NCT06151717?
The interventions under investigation include: Non-Interventional Study (OTHER).
Who is sponsoring clinical trial NCT06151717?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI